Black Diamond Reports Promising Phase 2 Lung Cancer Data

Tip Ranks
2025.12.03 13:47
portai
I'm PortAI, I can summarize articles.

Black Diamond Therapeutics announced promising preliminary data from its Phase 2 trial of silevertinib for non-small cell lung cancer, showing a 60% objective response rate. The company plans a Phase 2 trial for glioblastoma in 2026. Despite financial challenges, the recent strategic partnership with Servier offers potential benefits. Analysts have mixed views on BDTX stock, with a recent Buy rating and a $9.00 price target, but also a high-risk assessment due to weak financials.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

The latest announcement is out from Black Diamond Therapeutics ( (BDTX) ).

On December 3, 2025, Black Diamond Therapeutics announced preliminary data from its Phase 2 trial of silevertinib in frontline non-small cell lung cancer (NSCLC) patients with non-classical EGFR mutations, showing a 60% objective response rate and 86% CNS response rate. The company plans to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed glioblastoma (GBM) patients in the first half of 2026, with preliminary data expected in 2028, highlighting the potential of silevertinib as a targeted therapy for EGFR-altered GBM.

The most recent analyst rating on (BDTX) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Black Diamond Therapeutics stock, see the BDTX Stock Forecast page.

Spark’s Take on BDTX Stock

According to Spark, TipRanks’ AI Analyst, BDTX is a Underperform.

Black Diamond Therapeutics is currently a high-risk investment due to its weak financial performance characterized by zero revenue and negative cash flow. The technical analysis suggests continued volatility, and the valuation highlights typical challenges of early-stage biotech firms. However, the recent strategic partnership with Servier offers potential long-term benefits. The overall score reflects the significant financial challenges and current market sentiment, with potential upside from successful execution of its strategic initiatives.

To see Spark’s full report on BDTX stock, click here.

More about Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company focused on developing MasterKey therapies targeting families of oncogenic mutations in cancer patients. Their therapies aim to address a wide range of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and penetrate the brain to treat central nervous system diseases.

Average Trading Volume: 1,013,521

Technical Sentiment Signal: Buy

Current Market Cap: $214.8M

For an in-depth examination of BDTX stock, go to TipRanks’ Overview page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer